unknown
Stage
About
Acrivon develops targeted precision oncology therapies using its proprietary AP3 platform to match drug mechanisms with the biological drivers of cancer, focusing on DNA damage response and kinase inhibitors in clinical development.
Explore Acrivon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.